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ABSTRACT 
 
The associations of polymorphisms of the chemokine genes (+1931А/Т MIP1β, A/G I-TAC (rs4512021), 
-403A/G RANTES, C/G MCP1 (rs2857657), -801G/A SDF1) with arterial hypertension and renal insufficiency 
were investigated in 238 patients with chronic glomerulonephritis and 462 individuals of the control group. It 
has been established that the genetic marker А I-TAC (rs 4512021) is the risk factor for genesis of the severe 
arterial hypertension at the chronic glomerulonephritis (OR=1,65) and the genotypes АА and AG I-TAC are the 
risk factors of depression of the kidney function. 
Keywords: chronic glomerulonephritis, arterial hypertension, glomerular filtration rate, creatinine rate, genetic 
polymorphism, chemokines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Corresponding author 
 
          ISSN: 0975-8585 
September - October 2014  RJPBCS   5(5)  Page No. 1104 
INTRODUCTION 
 
Chronic glomerulonephritis (CGN) is a multi-factor progressive kidney disease as the result of which a 
long-standing inflammatory process is developed which proceeds undulately which results in the genesis of 
sclerosis, hyalinosis, desolation of glomerular filtration function, genesis of the chronic kidney disease. [1,2]. 
 
Chronic glomerulonephritis more often than the other kidney disorders results is genesis of arterial 
hypertension (AH). There is a strong interrelation between arterial hypertension and kidney functional status. 
The failure of the kidney function lying in the insufficient sodium and water clearance rate is considered to be 
the most significant pathogenic link of the essential hypertension [3-5].  
 
Among the immune factors of the CGN genesis an important role belongs the chemotactic factors 
(chemokines) that control migration of leucocytes of different kinds to the area of inflammation; activate the 
motile cells, have an impact on the production of anti-inflammatory cytokines. [6]. 
 
Therefore, the researchers demonstrate the increasing interest in the polymorphic chemokine genes 
in respect of the kidney disorders [7, 8, 9] referring them to the potential genetic glomerulopathy risk factors. 
In pursuance of the foregoing within this research there has been performed the study of the role of genetic 
chemokine polymorphisms (+1931А/Т MIP1β, A/G I-TAC (rs4512021), -403A/G RANTES , C/G MCP1 
(rs2857657), -801G/A SDF1) in formation of arterial hypertension and depression of the kidney function in 
patients with chronic glomerulonephritis. 
 
MATERIALS AND PROCEDURES 
 
There was performed analysis of polymorphisms of the chemokine genes in 700 persons: 238 patients 
with chronic glomerulonephritis and 462 persons of the control group (average age 39,58±14,58 years varying 
from 15 to 76 years) and 462 persons of the control group (42,20±6,28 years varying from 18 to 79 years, 
p>0,05). The patient and control samplings included the Russian individuals born in the Central Black Earth 
Region of Russia and being unrelated against each other. The patients were included in a patients’ group only 
after making the diagnosis confirmed by means of the clinical and laboratory and instrumental examination 
techniques. The clinical-laboratory examination of the patients was carried out on the basis of the nephrology 
department by the Belgorod Regional Clinical Hospital. 
 
During the period of the blood sampling (surveying) when the patients were in inpatient treatment for 
the term from two to four weeks the blood pressure (BP) was measured daily. Further on at the outpatient 
stage the patients were keeping a diary of the blood pressure (BP) measurements with everyday blood 
pressure measurement carried out by themselves and examination by a nephrologist once a month within a 
period from 6 months up to 1 year. The AH criteria were systolic blood pressure (SBP)≥140 mm Hg and/or 
diastolic blood pressure (DBP)≥90 mm Hg. The AH was considered to be severe at BP ≥160/100 mm Hg in the 
course of treatment with antihypertensive drugs.  
 
The general clinical examination of the patients included detailed study of the disease history, 
physical examination, complete blood count, common urine analysis with microscopic evaluation of urine 
sediment, determination of the daily proteinuria, blood biomedical measurement (total protein, albumin, 
protein fractions, creatinine, uric acid, urea, cholesterol), glomerular filtration rate (calculation according to 
the Cockroft-Gault formula, 1976). 
 
The exclusionary criteria for a group of the CGN patients were diabetes mellitus (in the patient’s 
history or detected during examination), high blood pressure.  
 
The venous blood (8-9 ml) taken from the median cubital vein of the proband was used as the test 
material. Extraction of the genomic DNA from the peripheral blood was performed with the use of standard 
methods [10]. 
 
Analysis of all the locuses was carried out by means of the polymerase chain reaction (PCR) method of 
the DNA synthesis with the use of the standard oligonucleotide primers and probes [11-13]. 
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Genotyping assay of the DNA-markers was performed by means of the allelic discrimination analysis 
with the use of the TagMan probes. The associations of alleles and genotypes of the studied DNA-markers with 
arterial hypertensions in patients with chronic glomerulonephritis were evaluated by means of the 
contingency table analysis 2х2 with calculation of the 2 criterion with Yates’ correction for continuity and odd 
ratio (OR) with 95% confidence intervals (CI). By investigation of the figures of glomerular filtration rate and 
creatinine rate the median (Me) and interquartile range (Q25-Q75) was used, and for the comparative analysis 
– the Mann-Whitney test. («STATISTICA 6.0»). 
 
RESULTS 
 
The analysis of rates of genotypes of the studied polymorphic gene markers has shown that no 
statistically significant differences have been detected by comparative analysis of the rates of alleles and 
genotypes of the investigated chemokine locuses between the patients with CGN and the control group (Table 
1).  
Table 1: Summary information about the studied polymorphisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium. P values were calculated using the χ
2
 test. 
 
By evaluation of the BP level in the course of disease the patients were divided into three groups:  
patients with the BP<140/90 mm Hg (84 persons – 36,2%), BP from 140/90 to 159/100 mm Hg (96 persons – 
41,4%), BP>160/110 mm Hg (52 persons – 22,4%). It has been established that in patients with severe arterial 
hypertension (blood pressure 160/110 and more mm Hg) the concentration of the А I-TAC allele made 68,78% 
and is the highest as compares to the control group (56,04%, OR=1,65 95% CI 1,02-2,69, χ
 2
=4,13, p=0,04). 
 
By evaluation of the glomerular filtration rate (Fig.1) and creatinine rate (Fig.2) in patients with CGN 
depending in the genetic polymorphisms of chemokines there have been established the significant 
associations of these characteristics with the genetic polymorphism A/G I-TAC (rs 4512021).  
 
Figure 1: Associations of the genetic polymorphism A/G I - TAC (rs4512021) with the figures of the glomerular filtration 
in patients with CGN 
Polymorphism 
Studied 
groups 
Minor allele MAF (%) 
HWE 
χ2 p 
(+1931)А/Т MIP1β  
(+1931)А/Т MIP1β  
A/G I-TAC (rs4512021) 
A/G I-TAC (rs4512021) 
(-403)G/A RANTES  
(-403)G/A RANTES 
C/ G MCP-1 (rs2857657)  
C/ G MCP-1 (rs2857657)  
(-801)G/A SDF1  
(-801)G/A SDF1 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
(+1931)А MIP1β  
(+1931)А MIP1β  
G I-TAC (rs4512021) 
G I-TAC (rs4512021) 
(-403)A RANTES  
(-403)A RANTES  
G MCP-1 (rs2857657) 
G MCP-1 (rs2857657) 
(-801)A SDF1  
(-801) A SDF1  
27.78 
27.27 
39.07 
43.96 
17.12 
17.88 
18.86 
15.56 
17.04 
17.14 
1.24 
0.36 
0.10 
0.10 
0.52 
0.04 
0.67 
0.10 
0.46 
0.23 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
          ISSN: 0975-8585 
September - October 2014  RJPBCS   5(5)  Page No. 1106 
 
 
Figure 2: Creatinine rate in patients with CGN depending on the genetic polymorphism A/G I - TAC (rs 4512021) 
 
It has been found out that the patients with CGN with the genotypes АА and АG I-TAC has a 
significantly lower indicator of the glomerular filtration (Me 74,0 ml/min, Q25-Q75 14,0-104,0 ml/min) and a 
higher creatinine rate (Me 119,0 μmol/l, Q25-Q75 94,4-541,0 μmol/l) as compared to the individuals with GG 
genotype (Me 92,0 ml/min, Q25-Q75 74,0-108,0 ml/min, р=0,047 and Me 101,0 μmol/l, Q25-Q75 87,0– 81,0 
ml/min, р=0,05, respectively). 
 
DISCUSSION 
 
It has been found out that the polymorphic genetic marker A/G I-ТAC (rs 4512021) has a pleiotropic 
effect on formation of an expressed arterial hypertension in the course of CGN, determines the reduction of 
the glomerular filtration rate and increase in the creatinine rate in patients with CGN. 
 
The interferon chemokine the inducible α-chemo attractant of the T-cells is not only a relevant 
chemotactic factor for Т-lymphocytes but also has a significant role in activation of monocytes, natural killer 
cells in the inflammation area [12]. Its rate is regulated by interferon. The increase in concentration and 
activity of the separate leucocytes groups in the kidney glomerulus affected by the immune-inflammatory 
processes results in the enhanced production of the anti-inflammatory cytokines within the abnormal focus. 
The enhanced production of the cell response mediators, cytokines and growth factors provides the basis of 
the glomerulosclerosis genesis. By progressing not only in the affected but also in the remaining intact 
nephrons it causes the advance of glomerulonephritis and genesis of the chronic kidney disease [12, 13]. 
 
CONCLUSIONS 
 
Thus, the findings of the research allow deducing that the genetic marker А I-TAC (rs 4512021) is the 
risk factor in respect of progressing of the severe arterial hypertension in the course of the chronic 
glomerulonephritis (OR=1,65) and the АА and AG I-TAC genotypes are the risk factors that may cause 
depression of the kidney function. 
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